Selecta Biosciences Inc.

Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry 

Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA

Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas

Plus: Selecta, Sobi’s gout treatment meets in Phase III and updates from Zura, NIH and more

Plus: Shook promoted to CMO at Nkarta, and updates from HilleVax, Neurotech, Akero, LifeSci, Dunad and more

Plus: Blaine Davis named CFO at Selecta, and updates from Promontory, ARTHEx and Shionogi

In an unusual step, AAV developers are joining forces to address an old risk that DMD studies have put back in play

Plus Foster becomes venture partner and updates from Norwest, TCR2, PTC and more

Plus Selecta’s clinical hold, Allorion’s fund-raising and a Philogen-Janssen deal

AAVs still center stage, but next-gen approaches starting to attract more partners